Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327997 | 0.93 | HDAC6 (0.47) | MAPTTP53PPARGAPPSMN1; SMN2 | |
| SCHEMBL29327889 | 0.86 | MAPT (0.56) | MAPTTP53PPARGAPPSMN1; SMN2 | |
| SCHEMBL29327980 | 0.83 | MAPT (0.53) | MAPTTP53PPARGAPPSMN1; SMN2 | |
| SCHEMBL29327852 | 0.83 | HDAC3 (0.48) | MAPTTP53PPARGSMN1; SMN2NPC1 | |
| SCHEMBL29327844 | 0.83 | PPARG (0.60) | MAPTTP53PPARGSMN1; SMN2NPC1 | |
| SCHEMBL29327928 | 0.82 | APP (0.48) | MAPTTP53PPARGAPPSMN1; SMN2 | |
| SCHEMBL29327987 | 0.81 | PPARG (0.44) | TP53PPARGNPC1RAB9ATHRB | |
| SCHEMBL29327992 | 0.81 | PPARG (0.44) | MAPTTP53PPARGSMN1; SMN2NPC1 | |
| SCHEMBL29327818 | 0.81 | PPARG (0.70) | MAPTTP53PPARGSMN1; SMN2NPC1 | |
| SCHEMBL29327855 | 0.80 | PPARG (0.54) | MAPTTP53PPARGPTGESNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | MAPT 4591/4885TP53 1398/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.